PMID- 19673944
OWN - NLM
STAT- MEDLINE
DCOM- 20091124
LR  - 20131121
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 36
IP  - 5-6
DP  - 2009 May
TI  - Changes in the composition of the thoracic aortic wall in spontaneously 
      hypertensive rats treated with losartan or spironolactone.
PG  - 583-8
LID - 10.1111/j.1440-1681.2008.05116.x [doi]
AB  - 1. In the present study, we compared the elastin and collagen content of thoracic 
      aortic medial and adventitial layers from Wistar-kyoto (WKY) and spontaneously 
      hypertensive rats (SHR). In addition, the effects of losartan, an angiotensin II 
      receptor antagonist, and spironolactone, a mineralocorticoid receptor antagonist, 
      on collagen and elastin content were determined. 2. Prehypertensive (4-week-old) 
      and hypertensive (16-week-old) SHR were randomly divided into three groups 
      treated with either 0.9% NaCl, losartan (20 mg/kg per day) or spironolactone (200 
      mg/kg per day). Prehypertensive and hypertensive SHR were treated for 12 and 16 
      weeks, respectively. Age-matched WKY rats were not treated with NaCl, losartan or 
      spironolactone and served as the control group. 3. The medial and adventitial 
      layers of the thoracic aorta were composed mainly of elastin and collagen, 
      respectively, in both SHR and WKY rats. Compared with WKY rats, SHR exhibited 
      greater collagen and elastin content in the media, but decreased collagen and 
      elastin content in the adventitial layer. Both medial and adventitial collagen 
      and elastin content increased significantly with age in both strains and was 
      greater in 32-week-old rats compared with 16-week-old rats. Spironolactone 
      treatment decreased collagen content in the media of thoracic aortas from 
      prehypertensive SHR, whereas losartan decreased collagen content in the media of 
      aortas from hypertensive SHR. In contrast, neither spironolactone nor losartan 
      had any effect on adventitial collagen content in prehypertensive and 
      hypertensive SHR. Medial collagen and elastin were positively related to pulse 
      pressure (PP), but there was no correlation between adventitial mass or collagen 
      content and PP or mean arterial pressure in untreated and treated SHR and WKY 
      rats. 4. In conclusion, the composition of the medial and adventitial layers of 
      the thoracic aorta differs and treatment of SHR with losartan and spironolactone 
      decreases collagen content when delivered at the hypertensive or prehypertensive 
      stage, respectively. However, neither drug has any effect on adventitial collagen 
      content in SHR.
FAU - Han, Wei-Qing
AU  - Han WQ
AD  - Institute of Health Sciences, Shanghai Institutes for Biological Sciences, 
      Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, 
      Shanghai, China.
FAU - Wu, Ling-Yun
AU  - Wu LY
FAU - Zhou, Hai-Yan
AU  - Zhou HY
FAU - Zhang, Jia
AU  - Zhang J
FAU - Che, Zai-Qian
AU  - Che ZQ
FAU - Wu, Yong-Jie
AU  - Wu YJ
FAU - Liu, Jian-Jun
AU  - Liu JJ
FAU - Zhu, Ding-Liang
AU  - Zhu DL
FAU - Gao, Ping-Jin
AU  - Gao PJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081027
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Diuretics)
RN  - 27O7W4T232 (Spironolactone)
RN  - 9007-34-5 (Collagen)
RN  - 9007-58-3 (Elastin)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Animals
MH  - Antihypertensive Agents/pharmacology/therapeutic use
MH  - Aorta, Thoracic/*chemistry/drug effects/metabolism/*pathology
MH  - Blood Pressure/drug effects
MH  - Collagen/analysis/metabolism
MH  - Connective Tissue/chemistry/metabolism
MH  - Diuretics/pharmacology/therapeutic use
MH  - Drug Evaluation, Preclinical
MH  - Elastin/analysis/metabolism
MH  - Hypertension/*drug therapy/*pathology/physiopathology
MH  - Losartan/pharmacology/*therapeutic use
MH  - Muscle, Smooth, Vascular/chemistry/drug effects/metabolism
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
MH  - Spironolactone/pharmacology/*therapeutic use
EDAT- 2009/08/14 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/08/14 09:00
PHST- 2009/08/14 09:00 [entrez]
PHST- 2009/08/14 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - CEP5116 [pii]
AID - 10.1111/j.1440-1681.2008.05116.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2009 May;36(5-6):583-8. doi: 
      10.1111/j.1440-1681.2008.05116.x. Epub 2008 Oct 27.